Vertex Pharma (VRTX) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY26 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $558.88 +3.50%
Revenue Growth %: +10.7%
Financial Fact:
Loss from operations: -18.73M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Revenue Growth %: +10.7%
Financial Fact:
Loss from operations: -18.73M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $4.73, $0.01 better than the analyst estimate of $4.72. Revenue for the quarter came in at $3.33 billion versus the consensus estimate of $3.22 billion.
GUIDANCE:
Vertex Pharma sees FY2026 revenue of $13.1-13.2 billion, versus the consensus of $13.05 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Updates US Conviction List Directors' Cut
- Oppenheimer Holdings (OPY) Reports Q3 EPS of $1.81
- Citi reiterates neutral rating on Okta amid data leak concerns
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
